Epigenetic biomarkers in the diagnosis of ovarian cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10
   PubMed Web of Science ®Google Scholar
• Seidman JD, Horkayne-Szakaly I, Haiba M, The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-4
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-66
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Klug TL, St John E, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7
   PubMed Web of Science ®Google Scholar
• Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984;50:765-9
   PubMed Web of Science ®Google Scholar
• Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12
   PubMed Web of Science ®Google Scholar
• Sjovall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol 2002;85:175-8
   PubMed Web of Science ®Google Scholar
• Jacobs I, Davies AP, Bridges J, Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993;306:1030-4
   PubMed Web of Science ®Google Scholar
• Skates SJ, Menon U, MacDonald N, Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21:206s-10s
   PubMedGoogle Scholar
• Menon U, Gentry-Maharaj A, Hallett R, Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40
   PubMed Web of Science ®Google Scholar
• Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009;6:e1000114
   PubMed Web of Science ®Google Scholar
• Gilbert L, Basso O, Sampalis J, Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol 2012;13:285-91
   PubMed Web of Science ®Google Scholar
• SEER cancer statistics review. National Cancer Institute. 2006. Available from: http://seer.cancer.gov/
   Google Scholar
• Meeuwissen PA, Seynaeve C, Brekelmans CT, Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 2005;97:476-82
   PubMed Web of Science ®Google Scholar
• Gaarenstroom KN, van der Hiel B, Tollenaar RAEM, Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006;16(Suppl 1):54-9
   PubMed Web of Science ®Google Scholar
• Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006;100:20-6
   PubMed Web of Science ®Google Scholar
• Oei AL, Massuger LF, Bulten J, Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 2006;94:814-19
   PubMed Web of Science ®Google Scholar
• Hermsen BB, Olivier RI, Verheijen RH, No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007;96:1335-42
   PubMed Web of Science ®Google Scholar
• Stirling D, Evans DG, Pichert G, Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 2005;23:5588-96
   PubMed Web of Science ®Google Scholar
• United Kingdom Familial Ovarian Cancer Screening Study. 2001. Available from: http://www.instituteforwomenshealth.ucl.ac.uk/academic_research/gynaecologicalcancer/gcrc/ukfocss
   Google Scholar
• Maggino T, Gadducci A, D'Addario V, Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54:117-23
   PubMed Web of Science ®Google Scholar
• Jacobs I, Oram D, Fairbanks J, A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9
   PubMedGoogle Scholar
• Hellstrom I, Raycraft J, Hayden-Ledbetter M, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700
   PubMed Web of Science ®Google Scholar
• Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-40
   PubMed Web of Science ®Google Scholar
• Skates SJ, Horick N, Yu Y, Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004;22:4059-66
   PubMed Web of Science ®Google Scholar
• Holliday R. The inheritance of epigenetic defects. Science 1987;238:163-70
   PubMed Web of Science ®Google Scholar
• Richardson B, Yung R. Role of DNA methylation in the regulation of cell function. J Lab Clin Med 1999;134:333-40
   PubMed Web of Science ®Google Scholar
• Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science 2001;293:1089-93
   PubMed Web of Science ®Google Scholar
• Doi A, Park IH, Wen B, Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009;41:1350-3
   PubMed Web of Science ®Google Scholar
• Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-13
   PubMed Web of Science ®Google Scholar
• Ng HH, Bird A. DNA methylation and chromatin modification. Curr Opin Genet Dev 1999;9:158-63
   PubMed Web of Science ®Google Scholar
• Surani MA. Imprinting and the initiation of gene silencing in the germ line. Cell 1998;93:309-12
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Ladd-Acosta C, Wen B, The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009;41:178-86
   PubMed Web of Science ®Google Scholar
• Luger K, Mader AW, Richmond RK, Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997;389:251-60
   PubMed Web of Science ®Google Scholar
• Wang H, Cao R, Xia L, Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell 2001;8:1207-17
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002;12:198-209
   PubMed Web of Science ®Google Scholar
• Verdone L, Agricola E, Caserta M, Di Mauro E. Histone acetylation in gene regulation. Brief Funct Genomic Proteomic 2006;5:209-21
   PubMedGoogle Scholar
• Fraga MF, Ballestar E, Montoya G, The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. M Nucleic Acids Res 2003;31:1765-74
   PubMed Web of Science ®Google Scholar
• Jones PL, Veenstra GJ, Wade PA, Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-91
   PubMed Web of Science ®Google Scholar
• Fuks F, Hurd PJ, Wolf D, The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278:4035-40
   PubMed Web of Science ®Google Scholar
• Vire E, Brenner C, Deplus R, The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871-4
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31
   PubMed Web of Science ®Google Scholar
• Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005;15:563-8
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59
   PubMed Web of Science ®Google Scholar
• Esteller M, Fraga MF, Guo M, DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001;10:3001-7
   PubMed Web of Science ®Google Scholar
• Suzuki H, Watkins DN, Jair KW, Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-22
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92
   PubMed Web of Science ®Google Scholar
• Gama-Sosa MA, Slagel VA, Trewyn RW, The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983;11:6883-94
   PubMed Web of Science ®Google Scholar
• Chen RZ, Pettersson U, Beard C, DNA hypomethylation leads to elevated mutation rates. Nature 1998;395:89-93
   PubMed Web of Science ®Google Scholar
• Gaudet F, Hodgson JG, Eden A, Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489-92
   PubMed Web of Science ®Google Scholar
• Hanada M, Delia D, Aiello A, bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82:1820-8
   PubMed Web of Science ®Google Scholar
• Hatada I, Fukasawa M, Kimura M, Genome-wide profiling of promoter methylation in human. Oncogene 2006;25:3059-64
   PubMed Web of Science ®Google Scholar
• Nishigaki M, Aoyagi K, Danjoh I, Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res 2005;65:2115-24
   PubMed Web of Science ®Google Scholar
• Kondo Y, Shen L, Cheng AS, Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008;40:741-50
   PubMed Web of Science ®Google Scholar
• Cao R, Wang L, Wang H, Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-43
   PubMed Web of Science ®Google Scholar
• Raaphorst FM, Meijer CJLM, Fieret E, Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003;5:481-8
   PubMed Web of Science ®Google Scholar
• Cao W, Feng Z, Cui Z, Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer 2011; published online 11 October 2011; doi: 10.1002/cncr.26575
   Google Scholar
• Yu J, Yu J, Rhodes DR, A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007;67:10657-63
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-9
   PubMed Web of Science ®Google Scholar
• Voorhoeve PM, le Sage C, Schrier M, A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006;124:1169-81
   PubMed Web of Science ®Google Scholar
• Schultz J, Lorenz P, Gross G, MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008;18:549-57
   PubMed Web of Science ®Google Scholar
• Calin GA, Ferracin M, Cimmino A, A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801
   PubMed Web of Science ®Google Scholar
• Augoff K, McCue B, Plow EF, Sossey-Alaoui K. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer 2012;11:5
   PubMed Web of Science ®Google Scholar
• Brueckner B, Stresemann C, Kuner R, The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007;67:1419-23
   PubMed Web of Science ®Google Scholar
• Suzuki H, Takatsuka S, Akashi H, Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res 2011;71:5646-58
   Google Scholar
• Garzon R, Liu S, Fabbri M, MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009;113:6411-18
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Visvanathan K, Roden R, Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008;198:351-6
   PubMed Web of Science ®Google Scholar
• Piek JM, van Diest PJ, Zweemer RP, Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-6
   PubMed Web of Science ®Google Scholar
• Medeiros F, Muto MG, Lee Y, The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230-6
   PubMed Web of Science ®Google Scholar
• Callahan MJ, Crum CP, Medeiros F, Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007;25:3985-90
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-43
   PubMed Web of Science ®Google Scholar
• Dehari R, Kurman RJ, Logani S, Shih IeM. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 2007;31:1007-12
   PubMed Web of Science ®Google Scholar
• Choi YL, Kang SY, Shin YK, Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch 2006;448:331-6
   PubMed Web of Science ®Google Scholar
• Yoon JH, Dammann R, Pfeifer GP. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 2001;94:212-17
   PubMed Web of Science ®Google Scholar
• Rathi A, Virmani AK, Schorge JO, Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 2002;8:3324-31
   PubMed Web of Science ®Google Scholar
• Makarla PB, Saboorian MH, Ashfaq R, Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005;11:5365-9
   PubMed Web of Science ®Google Scholar
• Feng Q, Deftereos G, Hawes SE, DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. Gynecol Oncol 2008;111:320-9
   PubMed Web of Science ®Google Scholar
• Bol GM, Suijkerbuijk KP, Bart J, Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology 2010;57:363-70
   PubMed Web of Science ®Google Scholar
• Ibanez de Caceres I, Battagli C, Esteller M, Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004;64:6476-81
   PubMed Web of Science ®Google Scholar
• Song MS, Song SJ, Ayad NG, The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004;6:129-37
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15
   PubMed Web of Science ®Google Scholar
• Baldwin RL, Nemeth E, Tran H, BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000;60:5329-33
   PubMed Web of Science ®Google Scholar
• Strathdee G, Appleton K, Illand M, Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001;158:1121-7
   PubMed Web of Science ®Google Scholar
• Wilcox CB, Baysal BE, Gallion HH, High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 2005;159:114-22
   PubMed Web of Science ®Google Scholar
• Wiley A, Katsaros D, Chen H, Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006;107:299-308
   PubMed Web of Science ®Google Scholar
• Antoniou A, Pharoah PD, Narod S, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30
   PubMed Web of Science ®Google Scholar
• Futreal PA, Liu Q, Shattuck-Eidens D, BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2
   PubMed Web of Science ®Google Scholar
• Dworkin AM, Spearman AD, Tseng SY, Methylation not a frequent "second hit" in tumors with germline BRCA mutations. Fam Cancer 2009;8:339-46
   PubMed Web of Science ®Google Scholar
• Collins Y, Dicioccio R, Keitz B, Methylation of death-associated protein kinase in ovarian carcinomas. Int J Gynecol Cancer 2006;16(Suppl 1):195-9
   PubMed Web of Science ®Google Scholar
• Hafner N, Diebolder H, Jansen L, Hypermethylated DAPK in serum DNA of women with uterine leiomyoma is a biomarker not restricted to cancer. Gynecol Oncol 2011;121:224-9
   PubMed Web of Science ®Google Scholar
• Sellar GC, Watt KP, Rabiasz GJ, OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003;34:337-43
   Google Scholar
• Chen H, Ye F, Zhang J, Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma. Eur J Gynaecol Oncol 2007;28:464-7
   PubMed Web of Science ®Google Scholar
• Czekierdowski A, Czekierdowska S, Szymanski M, Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer. Neuro Endocrinol Lett 2006;27:609-13
   PubMed Web of Science ®Google Scholar
• Zhou F, Cao X, Liu M, A study of the methylation status of opioid binding protein/cell adhesion molecule-like gene in ovarian cancer using nested methylation-specific polymerase chain reaction detection. Clin Lab 2011;57:421-4
   PubMed Web of Science ®Google Scholar
• Tam KF, Liu VW, Liu SS, Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol 2007;133:331-41
   PubMed Web of Science ®Google Scholar
• Su HY, Lai HC, Lin YW, An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 2009;124(2):387-93
   PubMed Web of Science ®Google Scholar
• Melnikov A, Scholtens D, Godwin A, Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn 2009;11:60-5
   PubMed Web of Science ®Google Scholar
• Cheng P, Schmutte C, Cofer KF, Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br J Cancer 1997;75:396-402
   PubMed Web of Science ®Google Scholar
• Qu G, Dubeau L, Narayan A, Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat Res 1999;423:91-101
   PubMed Web of Science ®Google Scholar
• Widschwendter M, Jiang G, Woods C, DNA hypomethylation and ovarian cancer biology. Cancer Res 2004;64:4472-80
   PubMed Web of Science ®Google Scholar
• Czekierdowski A, Czekierdowska S, Wielgos M, The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro Endocrinol Lett 2006;27:381-6
   PubMed Web of Science ®Google Scholar
• Cheng W, Jiang Y, Liu C, Identification of aberrant promoter hypomethylation of HOXA10 in ovarian cancer. J Cancer Res Clin Oncol 2010;136:1221-7
   PubMed Web of Science ®Google Scholar
• Grunau C, Brun ME, Rivals I, BAGE hypomethylation, a new epigenetic biomarker for colon cancer detection. Cancer Epidemiol Biomarkers Prev 2008;17:1374-9
   PubMed Web of Science ®Google Scholar
• Galusca B, Dumollard JM, Lassandre S, Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia. Virchows Arch 2005;447:18-23
   PubMed Web of Science ®Google Scholar
• Wei Y, Xia W, Zhang Z, Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008;47:701-6
   PubMed Web of Science ®Google Scholar
• Guo J, Cai J, Yu L, EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci 2011;102:530-9
   PubMed Web of Science ®Google Scholar
• Emmanuel C, Gava N, Kennedy C, Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS ONE 2011;6:e17617
   PubMed Web of Science ®Google Scholar
• Abbosh PH, Montgomery JS, Starkey JA, Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 2006;66:5582-91
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014-19
   PubMed Web of Science ®Google Scholar
• Caslini C, Capo-chichi CD, Roland IH, Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 2006;25:5446-61
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G, MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-707
   PubMed Web of Science ®Google Scholar
• Dahiya N, Sherman-Baust CA, Wang TL, MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE 2008;3:e2436
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Hernandez-Herrera A, Jacobsen A, Integrated Analyses of microRNAs Demonstrate Their Widespread Influence on Gene Expression in High-Grade Serous Ovarian Carcinoma. PLoS ONE 2012;7:e34546
   PubMed Web of Science ®Google Scholar
• Resnick KE, Alder H, Hagan JP, The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009;112:55-9
   PubMed Web of Science ®Google Scholar
• Jones S, Wang TL, Shih IeM, Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228-31
   PubMed Web of Science ®Google Scholar
• Wiegand KC, Shah SP, Al-Agha OM, ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43
   PubMed Web of Science ®Google Scholar
• Frommer M, McDonald LE, Millar DS, A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992;89:1827-31
   PubMed Web of Science ®Google Scholar
• Suijkerbuijk KP, van Diest PJ, van der Wall E. Improving early breast cancer detection: focus on methylation. Ann Oncol 2011;22:24-9
   PubMedGoogle Scholar
• Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997;25:2532-4
   PubMed Web of Science ®Google Scholar
• Nygren AO, Ameziane N, Duarte HM, Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005;33:e128
   PubMed Web of Science ®Google Scholar
• Weber M, Davies JJ, Wittig D, Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005;37:853-62
   PubMed Web of Science ®Google Scholar
• Serre D, Lee BH, Ting AH. MBD-isolated Genome Sequencing provides a high-throughput and compre¬hensive survey of DNA methylation in the human genome. Nucleic Acids Res 2010;38:391-9
   PubMed Web of Science ®Google Scholar
• Nair SS, Coolen MW, Stirzaker C, Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias. Epigenetics 2011;6:34-44
   PubMed Web of Science ®Google Scholar
• Li M, Chen WD, Papadopoulos N, Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009;27:858-63
   PubMed Web of Science ®Google Scholar
• Gopalappa C, Das TK, Enkemann S, Eschrich S. Removal of hybridization and scanning noise from microarrays. IEEE Trans Nanobioscience 2009;8:210-18
   PubMed Web of Science ®Google Scholar
• Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 2010;11:191-203
   PubMed Web of Science ®Google Scholar
• Meaburn E, Schulz R. Next generation sequencing in epigenetics: insights and challenges. Semin Cell Dev Biol 2012;23:192-9
   PubMed Web of Science ®Google Scholar
• Mardis ER. A decade's perspective on DNA sequencing technology. Nature 2011;470:198-203
   PubMed Web of Science ®Google Scholar
• Warnecke PM, Stirzaker C, Melki JR, Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA. Nucleic Acids Res 1997;25:4422-6
   PubMed Web of Science ®Google Scholar
• Wojdacz TK, Thestrup BB, Cold S, No difference in the frequency of locus-specific methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls. Future Oncol 2011;7:1451-5
   PubMed Web of Science ®Google Scholar
• Flusberg BA, Webster DR, Lee JH, Direct detection of DNA methylation during single molecule, real-time sequencing. Nat Methods 2010;7:461-5
   PubMed Web of Science ®Google Scholar
• Minard ME, Jain AK, Barton MC. Analysis of epigenetic alterations to chromatin during development. Genesis 2009;47:559-72
   PubMed Web of Science ®Google Scholar
• Jayani RS, Ramanujam PL, Galande S. Studying histone modifications and their genomic functions by employing chromatin immunoprecipitation and immunoblotting. Methods Cell Biol 2010;98:35-56
   PubMed Web of Science ®Google Scholar
• Su X, Ren C, Freitas MA. Mass spectrometry-based strategies for characterization of histones and their post-translational modifications. Expert Rev Proteomics 2007;4:211-25
   PubMed Web of Science ®Google Scholar
• Stewart NA, Veenstra TD. Sample preparation for mass spectrometry analysis of formalin-fixed paraffin embedded tissue: proteomic analysis of formalin-fixed tissue. Methods Mol Biol 2008;425:131-8
   PubMedGoogle Scholar
• Peng L, Yuan Z, Ling H, SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities. Mol Cell Biol 2011;31:4720-34
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A, Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400
   PubMed Web of Science ®Google Scholar
• Lee WH, Morton RA, Epstein JI, Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-7
   PubMed Web of Science ®Google Scholar
• Cairns P, Esteller M, Herman JG, Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001;7:2727-30
   PubMed Web of Science ®Google Scholar
• Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol 2007;40:142-50
   PubMedGoogle Scholar
• Maekita T, Nakazawa K, Mihara M, High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006;12:989-95
   PubMed Web of Science ®Google Scholar
• Nakajima T, Maekita T, Oda I, Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 2006;15:2317-21
   PubMed Web of Science ®Google Scholar
• Piek JM, Verheijen RH, Kenemans P, BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol 2003;90:491
   PubMed Web of Science ®Google Scholar
• Hermsen BB, van Diest PJ, Berkhof J, Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer 2006;119:1412-18
   PubMed Web of Science ®Google Scholar
• Piek JM, Kenemans P, Zweemer RP, Ovarian carcinogenesis, an alternative theory. Gynecol Oncol 2007;107:355
   PubMed Web of Science ®Google Scholar
• Piek JM, van Diest PJ, Verheijen RH. Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Biol 2008;622:79-87
   PubMed Web of Science ®Google Scholar
• Piek JM, Verheijen RH, van Diest PJ. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2009;54:494-5
   PubMed Web of Science ®Google Scholar
• Hagen MA, Kooij MI, van Diest PJ, Hereditary serous carcinogenesis, update of a hypothesis. Eur J Clin Med Oncol 2011; Epub ahead of print
   Google Scholar
• Human Epigenome Project. Available from: http://www.epigenome.org/
   Google Scholar
• Shaw RJ, Akufo-Tetteh EK, Risk JM, Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. Nucleic Acids Res 2006;34:e78
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Mikeska T, Krypuy M, Dobrovic A. Sensitive melting analysis after real time- methylation specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res 2008;36:e42
   PubMed Web of Science ®Google Scholar
• Lofton-Day C, Model F, Devos T, DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008;5:414-23
   Web of Science ®Google Scholar
• Warren JD, Xiong W, Bunker AM, Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med 2011;9:133
   PubMed Web of Science ®Google Scholar
• Seeber LM, Zweemer RP, Marchionni L, Methylation profiles of endometrioid and serous endometrial cancer. Endocr Relat Cancer 2010;17:663-73
   PubMed Web of Science ®Google Scholar
• Houshdaran S, Hawley S, Palmer C, DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS ONE 2010;5:e9359
   Web of Science ®Google Scholar
• van der Meide WF, Snellenberg S, Meijer CJ, Promoter methylation analysis of WNT/beta-catenin signaling pathway regulators to detect adenocarcinoma or its precursor lesion of the cervix. Gynecol Oncol 2011;123:116-22
   PubMed Web of Science ®Google Scholar
• Cho NY, Kim JH, Moon KC, Kang GH. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch 2009;454:17-23
   PubMed Web of Science ®Google Scholar
• Licchesi JD, Westra WH, Hooker CM, Herman JG. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 2008;14:2570-8
   PubMed Web of Science ®Google Scholar
• Moelans CB, Verschuur-Maes AH, van Diest PJ. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 2011;225:222-31
   PubMed Web of Science ®Google Scholar
• Lee Y, Miron A, Drapkin R, A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35
   PubMed Web of Science ®Google Scholar
• Bijron JG, Van der Groep P, Van Dorst EB, Promoter hypermethylation patterns in Fallopian tube epithelium of BRCA1 and BRCA2 germline mutation carriers. Endocr Relat Cancer 2012;19:69-81
   PubMed Web of Science ®Google Scholar
• Wiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer 2006;16:210-18
   PubMed Web of Science ®Google Scholar
• Feng W, Marquez RT, Lu Z, Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 2008;112:1489-502
   Google Scholar